BIOTEC-NSTDA, King Mongkut's University of Technology Thonburi (KMUTT) and BioNet-Asia Company Limited entered into an MOU to collaborate on quality control for vaccine development. The MOU signing ceremony was held on 29 March 2012 at KMUTT. Representing three parties were Mr. Vitoon Vonghangool, Managing Director of BioNet-Asia, Dr. Sakarindr Bhumiratana, KMUTT President, and Dr. Suvit Tia, BIOTEC Deputy Executive Director.

This collaboration marks the beginning of a partnership between public and private sectors to develop biomaterial and vaccine under international standardized quality control.  The aims are to build up the capacity of the National Biopharmaceutical Facility (NBF) located at KMUTT on analytical techniques for vaccines, and to help accelerating the upstream production of pediatric vaccine combinations at BioNet-Asia facilities.

National Biopharmaceutical Facility (NBF) is a contract research and manufacturing organization, established under the collaboration between KMUTT and BIOTEC with financial support from Thai government. The unit serves as a center of excellence in science and technology to ensure self-reliance in the country for the production of drugs, vaccines and other high-value biomedical and biopharmaceutical products.

BioNet-Asia Co., Ltd. is a biotech company based in Thailand focusing on the development and marketing of vaccines in the emerging countries.